Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BCC 2025 | Using ctDNA in breast cancer clinical trials

Wolfgang Janni • 13 Mar 2025
BCC 2025
Breast Cancer
SURVIVE

Wolfgang Janni, MD, PhD, University of Ulm, Ulm, Germany, discusses liquid biopsy in breast cancer trials, including the SURVIVE study (NCT05658172) which investigated overall survival (OS) in standard care surveillance compared to intensified surveillance using liquid biopsy. Multiple trials monitor molecular relapse using circulating tumor DNA (ctDNA), and patients who display no distant metastasis on imaging are candidates for early-monitoring trials. This interview took place at the 2025 St. Gallen International Breast Cancer Consensus Meeting in Vienna, Austria.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Wolfgang Janni

SURVIVE: liquid biopsy-guided surveillance in early breast cancer
2:19
SURVIVE: liquid biopsy-guided surveillance in early breast cancer
Wolfgang Janni • 13 Mar 2025
The emerging role of ctDNA in screening & monitoring early breast cancer
0:41
The emerging role of ctDNA in screening & monitoring early breast cancer
Wolfgang Janni • 13 Mar 2025
Evaluating liquid biopsies in early breast cancer at St Gallen 2025
1:44
Evaluating liquid biopsies in early breast cancer at St Gallen 2025
Wolfgang Janni • 13 Mar 2025
Current and future HER2+, HR- metastatic breast cancer treatment approaches
2:24
Current and future HER2+, HR- metastatic breast cancer treatment approaches
Wolfgang Janni • 14 Sep 2024

Related Videos

How will SARMs fit into the current breast cancer treatment paradigm?
1:14
How will SARMs fit into the current breast cancer treatment paradigm?
Rafael Grochot • 2 Jul 2026
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
1:35
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
Rafael Grochot • 2 Jul 2026
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
1:07
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
Sanjoy Chatterjee • 17 May 2026
Design and aim of the HYPORT study in regional nodal breast cancer
1:23
Design and aim of the HYPORT study in regional nodal breast cancer
Sanjoy Chatterjee • 17 May 2026
The content of VJOncology is intended for healthcare professionals